The Tissue Core provides staff and technology dedicated to enhancing sample integrity and usability through use of optimized harvesting procedures;multi-modality preservation and processing;histopathologic- molecular morphologic characterization;and computerized inventory and web-based request and tracking systems. All aspects of sample identification, processing and storage are performed with strict compliance to the College of American Pathologists (CAP) guidelines. In order to maximize sharing and integration of SPORE projects, the Tissue Core collects and makes available data derived from all distributed samples.
Specific Aims of SPORE Tissue Core: A. To acquire tissue samples from the operating room and SPORE Animal Research Core with optimized handling to maximize cell viability and/or minimize the warm-ischemic interval so as to meet the tissue accrual requirements for the Brain Tumor SPORE projects and trials. B. To perform quality control tests on archived tissue samples collected from the operating room and SPORE Animal Research Core, to ensure availability of adequate numbers of consistently handled specimens that will yield useable data for SPORE projects and clinical trials. C. To maintain a SPORE Tissue Core database containing demographic data, results from molecular analyses, and tissue distributions (internal and external) that will be linked to relational clinical databases maintained by the Biostatistics and Clinical Core. D. To provide routine and advanced tissue handling/processing and analytical techniques, including immunohistochemistry, chromogenic in situ hybridization (CISH), tissue microarray construction, laser capture micro-dissection, RNA extraction, and preparation of viable cells that will advance project hypothesis development and goal attainment.
|Hayes, Josie; Yu, Yao; Jalbert, Llewellyn E et al. (2017) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol :|
|Campbell, Brittany B; Light, Nicholas; Fabrizio, David et al. (2017) Comprehensive Analysis of Hypermutation in Human Cancer. Cell 171:1042-1056.e10|
|Neill, Evan; Luks, Tracy; Dayal, Manisha et al. (2017) Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol 132:171-179|
|Wiencke, John K; Koestler, Devin C; Salas, Lucas A et al. (2017) Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clin Epigenetics 9:10|
|Raleigh, David R; Solomon, David A; Lloyd, Shane A et al. (2017) Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol 19:78-88|
|Müller, Sören; Diaz, Aaron (2017) Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint. Front Genet 8:73|
|López, Giselle; Oberheim Bush, Nancy Ann; Berger, Mitchel S et al. (2017) Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathol Commun 5:38|
|Lee, Julieann; Solomon, David A; Tihan, Tarik (2017) The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neurooncol 132:1-11|
|Jahangiri, Arman; Nguyen, Alan; Chandra, Ankush et al. (2017) Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci U S A 114:E8685-E8694|
|Kline, Cassie N; Joseph, Nancy M; Grenert, James P et al. (2017) Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol 19:699-709|
Showing the most recent 10 out of 336 publications